18,020 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Acquired by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 18,020 shares of the company's stock, valued at approximately $5,987,000. Susquehanna Fundamental Investments LLC owned approximately 0.06% of Medpace as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of the company. Pallas Capital Advisors LLC increased its position in shares of Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock valued at $1,086,000 after buying an additional 2,101 shares in the last quarter. Barclays PLC increased its holdings in shares of Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after acquiring an additional 8,275 shares in the last quarter. Sanctuary Advisors LLC raised its position in shares of Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock worth $1,738,000 after purchasing an additional 844 shares during the period. SYM FINANCIAL Corp bought a new position in shares of Medpace during the 4th quarter valued at about $320,000. Finally, Tokio Marine Asset Management Co. Ltd. acquired a new position in shares of Medpace in the 4th quarter valued at approximately $9,335,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $298.55 on Monday. The stock has a 50 day moving average price of $313.79 and a 200 day moving average price of $331.60. The stock has a market capitalization of $8.58 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $3.06 by $0.61. The company had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same quarter in the prior year, the firm posted $3.20 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the topic of several research analyst reports. TD Cowen downgraded shares of Medpace from a "buy" rating to a "hold" rating and dropped their target price for the stock from $370.00 to $328.00 in a report on Monday, April 14th. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a report on Monday, March 24th. William Blair reaffirmed a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Truist Financial dropped their price target on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research note on Wednesday, April 23rd. Finally, Mizuho reduced their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research report on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Medpace presently has an average rating of "Hold" and a consensus price target of $349.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.